BPC-157 Dosage: Reconstitution and Protocol

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in human gastric juice. It has become one of the most popular peptides in the self-administered research community, used primarily for its purported effects on tissue healing, gut health, and inflammation. The animal research is extensive and genuinely interesting. The human evidence is not.

That gap between animal promise and human proof matters, and anyone using BPC-157 should understand exactly where the data stands before reconstituting their first vial.

The Evidence Problem

The BPC-157 literature contains hundreds of animal studies — mostly in rats — showing effects on tendon repair, ligament healing, gut mucosal protection, angiogenesis, and inflammation modulation. These studies are legitimate and peer-reviewed. Some of the results are striking.

Here is the problem: as of early 2026, there are approximately 3 published human clinical studies involving BPC-157, with roughly 30 total participants across them. That's it. The vast majority of what people believe about BPC-157 dosing, efficacy, and safety is extrapolated from rodent models.

Rodent-to-human extrapolation is a standard starting point in pharmacology, but it is not a finishing point. Doses that work in rats may not translate to equivalent effects in humans. Side effects that don't appear in short-term rodent studies may emerge in humans at different doses or durations. And the specific formulations, purity levels, and routes of administration used in published research may not match what's available from peptide suppliers.

None of this means BPC-157 doesn't work in humans. It means we don't yet have adequate data to know with confidence whether it does, at what dose, for what conditions, or with what risk profile. If you choose to use it, you should do so with informed awareness of that uncertainty — not because an internet forum told you it's "proven."

Typical Research Doses

The most commonly referenced dose range in the peptide community is 250-500 mcg per day, administered subcutaneously. This range comes from allometric scaling of rodent doses (typically 10 mcg/kg in rats) to estimated human-equivalent doses, combined with anecdotal reporting from users.

250 mcg/day: The lower end of the commonly used range. Often chosen as a starting dose, particularly for users new to peptides or using BPC-157 for general gut support rather than acute tissue repair.

500 mcg/day: The more commonly reported dose for users targeting musculoskeletal recovery (tendon, ligament, or joint issues). Some protocols split this into two 250 mcg injections per day (morning and evening), while others administer the full 500 mcg in a single injection.

Higher doses: Some users report doses up to 750-1000 mcg/day, but there is no published evidence supporting increased efficacy at these levels, and safety data is nonexistent. Higher doses consume vials faster and increase cost without established benefit.

Route of administration: Subcutaneous injection is the most common route. Some users take BPC-157 orally (it was originally studied as an oral agent for gut protection), and a small number of the human studies used oral administration. The bioavailability and distribution profile likely differs between oral and subcutaneous routes.

Reconstitution Math

BPC-157 is supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before injection. Getting the concentration right is straightforward arithmetic, but errors here mean dosing errors for every subsequent injection.

Standard Reconstitution: 5 mg Vial

The most common vial size is 5 mg. Here is the math for different reconstitution volumes:

Recommended approach: 2 mL of bacteriostatic water into a 5 mg vial. This yields 2500 mcg/mL, which makes the dose math clean and the syringe volumes easy to read on a standard 1 mL (100-unit) insulin syringe. Drawing 10 units gives you 250 mcg. Drawing 20 units gives you 500 mcg. No ambiguity.

Using 1 mL produces a more concentrated solution (less volume per injection, which some prefer), but the syringe volumes become very small — 5 units for 250 mcg — where graduation marks on some insulin syringes are hard to read accurately.

Reconstitution Procedure

1. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab.
2. Draw bacteriostatic water into a syringe. Use a standard syringe (not an insulin syringe) for easier volume measurement.
3. Inject the water into the vial slowly, aiming the stream at the glass wall rather than directly at the powder. Direct impact can damage the peptide structure.
4. Do not shake. Gently swirl or roll the vial between your palms until the powder is fully dissolved. The solution should be clear and colorless.
5. Label the vial with the reconstitution date, the concentration (e.g., "2500 mcg/mL"), and the volume added. This prevents dosing errors later.

How Many Doses Per Vial?

At 2 mL reconstitution volume from a 5 mg vial:

• At 250 mcg/day: 20 doses (20 days of use)
• At 500 mcg/day: 10 doses (10 days of use)

Plan your reconstitution around your protocol length. A 4-week cycle at 500 mcg/day requires approximately 3 vials (30 doses needed, 10 per vial).

Injection Protocol

Subcutaneous Injection Technique

BPC-157 is typically injected subcutaneously using an insulin syringe (29-31 gauge, 1/2 inch needle).

Site selection: The abdomen (at least 2 inches from the navel) is the most common site. Some users prefer to inject near the site of injury — for example, subcutaneously near a tendon that's being targeted — on the theory that local administration increases local concentration. There is no controlled human evidence confirming that localized injection produces superior outcomes to systemic subcutaneous injection, but the practice is widespread in the community.

Injection steps:

1. Clean the injection site with an alcohol swab and let it dry.
2. Draw your dose from the reconstituted vial using an insulin syringe.
3. Pinch a fold of skin at the injection site.
4. Insert the needle at a 45-degree angle into the subcutaneous tissue.
5. Inject slowly and steadily.
6. Withdraw the needle and apply light pressure with a clean swab if needed.
7. Dispose of the syringe in a sharps container.

Timing

There is no established optimal time of day for BPC-157 administration. Common practices include:

• Once daily (morning): Simplest protocol, easiest to track.
• Once daily (evening): Some users prefer this based on the theory that growth hormone release during sleep may synergize with BPC-157's effects. This is speculative.
• Twice daily (morning and evening): Used at 500 mcg/day by splitting into two 250 mcg injections. The rationale is more consistent peptide availability, though the pharmacokinetics of BPC-157 in humans are not well-characterized enough to know whether this matters.

Storage After Reconstitution

Reconstituted BPC-157 should be stored at 2-8C (36-46F) in the refrigerator, protected from light. Most users and suppliers suggest a shelf life of 14-28 days for reconstituted peptides mixed with bacteriostatic water. After that window, bacterial contamination risk increases and peptide degradation becomes a concern.

Do not freeze reconstituted peptides. Ice crystal formation during freezing can damage the peptide structure. Lyophilized (unreconstituted) vials can be stored frozen at -20C for long-term preservation.

See our peptide storage guide for detailed handling instructions.

Common Protocol Structures

These are community-reported protocols, not clinically validated treatment regimens:

Acute injury protocol (2-4 weeks):

• 500 mcg/day subcutaneous
• Single daily injection or split into 250 mcg twice daily
• Duration: until symptoms improve, typically 2-4 weeks

General maintenance protocol (4-6 weeks):

• 250 mcg/day subcutaneous
• Single daily injection
• Often cycled: 4 weeks on, 2-4 weeks off

Combined with TB-500 ("Wolverine stack"):

• BPC-157: 250-500 mcg/day
• TB-500: 2-5 mg twice weekly (separate injection)
• Duration: typically 4-6 weeks
• See our wolverine stack guide for more detail on this combination

What to Track

If you're using BPC-157, tracking matters more than usual precisely because the evidence base is thin. Your personal data becomes the primary feedback loop for whether the protocol is doing anything.

Log daily:

• Dose and time of administration
• Injection site
• Subjective symptom assessment (pain level, mobility, gut symptoms — whatever your target is)
• Any side effects (injection site redness, nausea, headache, dizziness)

Log weekly:

• Overall progress toward your goal
• Photos of injury site if applicable (visual progress documentation)
• Any changes to concurrent medications or supplements

Done Dose supports peptide tracking with reconstitution notes, dose calculations, and injection site logging. Given that BPC-157 involves daily injections over multi-week cycles, the rotation and tracking demands are higher than weekly GLP-1 medications.

Risks and Unknowns

Being honest about what we don't know is more useful than pretending the evidence is stronger than it is.

Unknown long-term safety: No human study has evaluated BPC-157 use beyond a few weeks. Long-term effects on angiogenesis (blood vessel formation), tumor biology, and organ function are unstudied in humans.

Angiogenesis concern: BPC-157 promotes new blood vessel growth in animal models. This is potentially beneficial for tissue repair. It is potentially harmful if it promotes vascularization of tumors. Anyone with a history of cancer or current malignancy should discuss this mechanism with their oncologist.

Purity and sourcing: BPC-157 is not manufactured under pharmaceutical-grade GMP conditions by the suppliers most people use. Purity, sterility, and actual peptide content can vary between vendors. Third-party testing certificates (from labs like Janoshik or HPLC analysis) provide some confidence, but the market is unregulated.

Drug interactions: Not studied. If you're taking anticoagulants, blood pressure medication, or immunosuppressants, the theoretical interaction profile is unknown.

FDA regulatory status: BPC-157 is not FDA-approved for any use. The FDA has included it in guidance documents regarding peptides used in compounding, which has affected its availability from compounding pharmacies. This regulatory landscape is evolving.

The Bottom Line

BPC-157 has an intriguing preclinical profile backed by hundreds of animal studies. It has an almost nonexistent human evidence base — roughly 3 studies with approximately 30 total participants. The reconstitution math is straightforward, the injection technique is standard subcutaneous, and the community-reported dosing of 250-500 mcg/day has been used by many thousands of people without widespread reports of serious adverse events.

That's what we know. Everything beyond that is extrapolation, anecdote, and informed speculation. If you're going to use BPC-157, track meticulously, source carefully, discuss it with a healthcare provider who understands peptides, and maintain realistic expectations about what the evidence can and cannot tell you.